Oncobiologics Inc., of Cranbury, N.J, filed to raise up to $115 million in an IPO. The number of shares and share price have not yet been disclosed. Oncobiologics, which develops biosimilar therapeutics – lead phase III-ready candidates ONS-3010 and ONS-1045 are biosimilar versions of Humira (adalimumab, Abbvie Inc.) and Avastin (bevacizumab, Roche AG), respectively – seeks a listing on Nasdaq under the ticker ONS.